Adenylosuccinate lyase deficiency

Douglas J Lanska MD MS MSPH

Neurogenetic Disorders

Updated 04.29.2024
Released 09.12.2003
Expires For CME 04.29.2027

Adenylosuccinate lyase deficiency

Author: Douglas J Lanska MD MS MSPH

See Contributor Disclosures

Adenylosuccinate lyase deficiency

In This Article

Quick Link

Introduction

Overview

Adenylosuccinate lyase deficiency is a rare, autosomal recessive defect of purine metabolism affecting purinosome assembly and reducing metabolite fluxes through both de novo purine synthesis (DNPS) and purine nucleotide recycling pathways. The purinosome is a multienzyme complex of DNPS enzymes (including adenylosuccinate lyase) that cells transiently assemble in their cytosol to address both depletion of and increased demand for purines. Clinically, adenylosuccinate lyase deficiency is generally categorized into three phenotypes: a fatal neonatal form, a severe form (type I), and a milder form (type II). Neurologic symptoms are the most common and prominent clinical problems associated with adenylosuccinate lyase deficiency. In the severe form of the disease, neurologic symptoms and signs are typically evident soon after birth. Common neurologic presentations include acute encephalopathy, chronic encephalopathy, and behavioral abnormalities in various nonspecific combinations with seizures and developmental delay or regression. Diagnosis of adenylosuccinate lyase deficiency may be delayed or missed because patients can present with nonspecific features, such as developmental delay, autism spectrum disorder, or epilepsy. Adenylosuccinate lyase deficiency can be diagnosed by detection of elevated metabolites along the DNPS pathway (succinylpurines) in body fluids. No specific FDA-approved treatment is available for adenylosuccinate lyase deficiency.

Key points

	• The clinical presentation of adenylosuccinate lyase deficiency varies greatly with respect to age of onset, clinical manifestations, and rate of disease progression.
	• Patients with adenylosuccinate lyase deficiency can present with nonspecific symptoms, such as developmental delay, autism spectrum disorder, or epilepsy, including infantile spasms.
	• Due to lack of specific features and later onset of symptoms, diagnosis is difficult.
	• Selective screening for adenylosuccinate lyase deficiency should be performed in infants who have neurologic disease without clear etiology, especially if supportive MRI findings are also present (eg, delayed or lack of myelination, abnormal white matter signal, and atrophy of the cerebrum or cerebellum).
	• Detection of succinylpurines in body fluids by high-performance liquid chromatography or liquid chromatography-tandem mass spectrometry is the preferred biochemical test for adenylosuccinate lyase deficiency.
	• No specific FDA-approved treatment is available for adenylosuccinate lyase deficiency.

Historical note and terminology

Origins of purine biochemistry. The word purine was coined by the German chemist Emil Fischer (1852-1919), who derived the German chemical term purin from the Latin purum uricum, for pure + uric acid; this was subsequently modified to an -ine ending in English, giving purine.

German chemist Emil Fischer (1852-1919)

Photo circa 1895. (Photograph by Atelier Victoria [owner Paul Gericke, founded 1894], Berlin.) (Public domain.)

Fischer, working at the University of Würzburg, synthesized purine for the first time in 1898. Purine is a specific, water-soluble, aromatic organic compound that consists of two heterocyclic rings (ie, a 6-member pyrimidine ring and a 5-member imidazole ring) fused together. Given the name that Fischer chose, it is perhaps not surprising that he employed uric acid as the starting material for the reaction sequence that led to purine.

Structural formula for purine

Structural formula for purine, with a numbered ring system. (Public domain.)
Structural formula of uric acid

(Public domain.)

Uric acid had been known for a century, having been isolated from kidney stones in 1776 by Swedish-German pharmaceutical chemist Carl Wilhelm Scheele (1742-1786).

Swedish-German pharmaceutical chemist Carl Wilhelm Scheele (1742-1786)

Engraving from Svenska Familj-Journalen (1874). (Public domain.)

In 1891, 7 years before his synthesis of purine, Fischer, in conjunction with German chemist Oscar Piloty (1866-1915), had synthesized the pentose L-ribose.

German chemist Oscar Piloty (1866-1915)

(Source: Harries C. Oskar Piloty [obituary]. Berichte der Deutschen chemischen Gesellschaft [A and B Series] 1920;53(9):A153-68.)

Piloty started studying chemistry under Adolf von Baeyer (1835-1917) at the University of Munich in 1888 but transferred to the University of Würzburg in 1889 to work with Fischer on the chemistry of sugars. Piloty transferred after Baeyer awarded him failing marks on an exam, but the low exam score did not reflect Piloty's knowledge or abilities and was apparently instead Bayer's adverse reaction when he learned that Piloty had fallen in love with his daughter. Piloty earned his PhD under Fischer in 1890, helped Fischer synthesize L-ribose from L-arabonic acid in 1891, then married Baeyer's daughter in 1892, and that same year followed Fischer to the University of Berlin. A family reconciliation ultimately occurred, and Piloty and his wife returned to Munich in 1900 when his father-in-law offered Piloty a position at the University of Munich (even though Fischer had made him a better offer).

Fischer received the 1902 Nobel Prize in chemistry (only the second ever awarded to this point) "in recognition of the extraordinary services he has rendered by his work on sugar and purine syntheses" (21). Baeyer subsequently received the 1905 Nobel Prize in chemistry "in recognition of his services in the advancement of organic chemistry and the chemical industry, through his work on organic dyes and hydroaromatic compounds."

After Fischer's pioneering work, purine biochemistry advanced markedly over the first half of the 20th century, in part propelled by his students. In 1909, Lithuanian-American biochemist Phoebus Levene (1869-1940) and his assistant (later associate), American Walter Jacobs (1883-1967), recognized that D-ribose was a natural product, the enantiomer of Fischer and Piloty's L-ribose, and an essential component of nucleic acids.

Lithuanian-American biochemist Phoebus Levene (1869-1940)

Photo circa 1920s. (Source: U.S. National Library of Medicine, Bethesda, Maryland.)

Levene had spent a summer with Fischer at the University of Berlin in 1902, and Jacobs had only recently earned his PhD in chemistry under Fischer in Berlin in 1907. When Jacobs returned to New York following his doctoral work in Germany, he was appointed as a postdoctoral fellow in Levene's laboratory at the newly established Rockefeller Institute for Medical Research. Not only did Levene ultimately discover the carbohydrate components of both RNA and DNA (ie, ribose and deoxyribose, respectively), but he also correctly inferred that DNA is composed of a series of nucleotides and discovered the order of the three major components of a single nucleotide (ie, phosphate-sugar-base). Unfortunately, although widely accepted for decades, Levene had, in fact, stumbled with his overly simplistic tetranucleotide hypothesis (1909), which proposed that DNA is composed of equal parts adenine, guanine, cytosine, and thymine, resulting from a repeating linear sequence of the four nucleotides (ie, tetranucleotide repeats).

The "tetranucleotide hypothesis" of the structure of DNA

The "tetranucleotide hypothesis" of the structure of DNA, proposed by Lithuanian-American biochemist Phoebus Levene in 1909, before DNA was understood to store genetic information. (Illustration created by Athel cb on 30 April ...

The genetic role of DNA was then unknown, and it was instead believed that Levene's proposed repeating structure excluded the possibility that DNA could store genetic information; instead, the protein component of chromosomes was then erroneously assumed to be the basis of heredity.

Several key steps beginning in the mid-1940s and extending to the early 1950s allowed a correct formulation of the structure of DNA: (1) demonstration that genes are composed of DNA, not protein; (2) discovery of "base pairing" through formulation of the Chargaff rules, which effectively disproved Levene's tetranucleotide hypothesis; (3) x-ray crystallography findings that indicated DNA had a helical structure. Work that began with Fischer ultimately culminated in the double helix model of deoxyribonucleic acid (DNA), by James Watson (b. 1928) and Francis Crick (1916-2004) in 1953.

Purine nucleosides and nucleotides. The purines as a class of molecules include the purine bases adenine (A, 6-amino-purine) and guanine (G, 2-amino-6-oxypurine), both of which can be synthesized in vivo from inosine monophosphate or can be obtained either from the diet or from breaking down and recycling existing compounds and derivatives.

Structural formula of the purine base adenine

(Public domain.)
Structural formula of the purine base guanine

(Public domain.)
Structural formula of inosine monophosphate

Inosine monophosphate (IMP) is a precursor of the purines adenosine and guanosine. (Public domain.)

The purine bases may be attached to the pentose sugar ribose to form the ribonucleosides adenosine and guanosine, respectively. Ribose exists in equilibrium in multiple forms: an open-chain form and cyclic forms with 5- or 6-member rings.

Structural formulas of the open-chain and cyclic forms of the pentose ribose

Several of the forms of D-ribose: the open-chain form (top), and Haworth projections of two of the four cyclic forms, alpha-D-ribopyranose (middle), and beta-D-ribofuranose (bottom). Ribose exists as a mixture of cyclic forms i...
Structural formula of the ribonucleoside adenosine

(Public domain.)
Structural formula of the ribonucleoside guanosine

(Public domain.)

The purine bases may also be attached to the pentose sugar deoxyribose to form the deoxyribonucleosides 2'-deoxyadenosine and 2-deoxyguanosine, respectively. Ribose also exists in equilibrium in multiple forms: an open-chain form and cyclic forms with 5- or 6-member rings.

Structural formula of a cyclic form of the pentose D-deoxyribose

Like D-ribose, D-deoxyribose has two cyclic or ring forms, deoxyribofuranose, with a five-membered ring, and deoxyribopyranose, with a six-membered ring. The form shown has a five-membered ring, so it is a deoxyribofuranose. De...
Chemical equilibrium of deoxyribose in solution

In aqueous solution, deoxyribose primarily exists as a mixture of three structures: the linear form and two ring forms, deoxyribofuranose with a five-membered ring, and deoxyribopyranose with a six-membered ring. The latter for...
Structural formula of the deoxyribonucleoside 2-deoxyadenosine

(Public domain.)
Structural formula of the deoxyribonucleoside 2'-deoxyguanosine

(Public domain.)

Addition of a phosphate group to the 5' carbon of ribose in the ribonucleosides adenosine and guanosine results in the formation of the ribonucleotides adenosine-5-monophosphate and guanosine-5-monophosphate, which are important metabolic and signaling molecules and building blocks of ribonucleic acid.

Structural formula of the ribonucleotide adenosine monophosphate

(Public domain.)
Structural formula of the ribonucleotide guanosine monophosphate

(Public domain.)

Addition of a phosphate group to the 5' carbon of deoxyribose in the deoxyribonucleosides 2-deoxyadenosine and 2'-deoxyadenoguanosine results in the formation of the deoxyribonucleotides deoxyadenosine monophosphate (dAMP; also known as deoxyadenylic acid or deoxyadenylate) and deoxyguanosine monophosphate (dGMP; also known as deoxyguanylic acid or deoxyguanylate), which are building blocks of deoxyribonucleic acid.

Structural formula of the deoxyribonucleotide deoxyadenosine monophosphate

dAMP; also known as deoxyadenylic acid or deoxyadenylate. (Public domain.)
Structural formula of the deoxyribonucleotide deoxyguanosine monophosphate

dGMP; also known as deoxyguanylic acid or deoxyguanylate. (Public domain.)

Examination of the structural components of adenosine triphosphate, the energy-carrying molecule that provides energy to drive many processes in living cells, will illustrate the components of nucleotides and nucleosides and how they are linked.

Structural formula of adenosine triphosphate

Structural formula of adenosine triphosphate (ATP), showing its chemical components, by name and by type or class of the component compounds. A purine base (adenine) is attached to a pentose (ribose) and that is attached to thr...

Adenylosuccinate lyase deficiency. Adenylosuccinate lyase deficiency, the first enzyme deficiency reported in the DNPS pathway in man, was discovered during a systematic study of amino acids in cerebrospinal fluid before and after acid hydrolysis (31). In three children with severe psychomotor retardation and autistic features, this procedure released abnormally large, equimolar amounts of aspartate and glycine. The additional identification by gas chromatography of an equimolar amount of ribose led to a search for purine compounds. Anion-exchange high-pressure liquid chromatography of deproteinized but not hydrolyzed cerebrospinal fluid, plasma, and urine revealed the presence of two UV-absorbing compounds that were undetectable in control samples: succinyl aminoimidazole carboxamide riboside (SAICA-riboside) and succinyl-adenosine (S-Ado). These succinylpurines are the products of the dephosphorylation by 5'-nucleotidases of succinyl aminoimidazole carboxamide ribotide (SAICAR) and succinyladenosine monophosphate (S-AMP, sometimes abbreviated SAMP), respectively.

Clinical manifestations

Presentation and course

	• Although the clinical picture of adenylosuccinate lyase deficiency is extremely variable, descriptive classification systems have generally identified three phenotypes: a fatal neonatal form, a severe form (type I), and a milder form (type II).
	• Neurologic symptoms are the most common and prominent clinical problems associated with adenylosuccinate lyase deficiency.
	• In the severe form of the disease, neurologic symptoms and signs are typically evident soon after birth.
	• Common neurologic presentations include acute encephalopathy, chronic encephalopathy, and behavioral abnormalities in various nonspecific combinations with seizures and developmental delay or regression.

Although the clinical picture of adenylosuccinate lyase deficiency is extremely variable, descriptive classification systems have generally identified three phenotypes: a fatal neonatal form, a severe form (type I), and a milder form (type II) (38; 41). However, the symptoms and signs of adenylosuccinate lyase deficiency vary along a continuum, and there are no fixed parameters to define phenotypic categories (40). Most adenylosuccinate lyase-deficient children are born after uncomplicated pregnancies with normal birth and family history. Neurologic symptoms are the most common and prominent clinical problems associated with adenylosuccinate lyase deficiency. In the severe form of the disease, neurologic symptoms and signs are typically evident soon after birth (14). Common neurologic presentations include acute encephalopathy, chronic encephalopathy, and behavioral abnormalities in various nonspecific combinations with seizures and developmental delay or regression (58; 14). Epilepsy is present in around 80% of the patients, with polymorphic and often intractable seizures (14). Less common features can include prolonged episodes of multifocal sustained myoclonic tremor (04).

In a study of clinical and molecular data from 18 patients of 13 unrelated families, age at onset ranged from birth to the first 3 years (median age 0.63 years), and age at diagnosis varied from 2 months to 17 years (median age 6.4 years) (57). The presenting sign was variously psychomotor delay (44%), epilepsy (17%), psychomotor delay and epilepsy (17%), and apneas, hypotonia, or nystagmus in single cases. One patient (sibling of a previously diagnosed child) had a presymptomatic diagnosis. All patients were definitively diagnosed with adenylosuccinate lyase deficiency based on pathogenic variants or biochemical assessment. The diagnosis was made by exome sequencing in approximately one third of cases. One patient (6%) had the fatal neonatal form, seven (39%) had type I, and nine (50%) had type II. Eighteen different variants, distributed along the entire adenylosuccinate lyase coding sequence, were predicted to variably impair either proper homotetramerization or catalytic activity of the enzyme. All but two variants were missense mutations.

Fatal neonatal form. Patients with a neonatal form presented with fatal neonatal encephalopathy with a lack of spontaneous movement (“floppy infant”), respiratory failure, and intractable seizures, which resulted in early death within the first weeks of life (83; 60; 38; 41; 48; 73). Clinical and radiologic results include severe epileptic encephalopathy and leukodystrophy with a vacuolar appearance of the brain (73). Adenylosuccinate lyase deficiency may also have prenatal manifestations with impaired intrauterine growth, microcephaly, fetal hypokinesia (with all its consequences up to arthrogryposis and pulmonary hypoplasia), and loss of fetal heart rate variability (60).

Type I adenylosuccinate lyase deficiency (severe). Most patients reported so far have adenylosuccinate lyase deficiency type I (severe form) presenting within the first months of life with a purely neurologic clinical picture characterized by severe psychomotor retardation, early onset of seizures that may be intractable, and postnatal microcephaly (49; 72; 83; 43; 62; 38; 41; 04; 05; 19). Further clinical evolution is characterized by developmental arrest, epileptic seizures, hypotonia (or hypertonia), abnormal involuntary movements (including paroxysmal dyskinesias, dystonias, tremor, and limb ataxia), autism spectrum disorder, and in some patients, coma vigil (ie, apparent unconsciousness with eyes open) (33; 45; 80; 43; 38; 41; 25; 48; 37; 08; 04; 05). Severe cortical visual impairment and impaired eye fixation and tracking, corresponding to the degree of encephalopathy, may also be a feature of the severe phenotype (48). With the exception of microcephaly, there are usually no dysmorphic features, although two patients have been reported with brachycephaly associated with a long, flat philtrum and thin upper lip (28).

Type II adenylosuccinate lyase deficiency (mild or moderate severity). Patients with adenylosuccinate lyase deficiency type II (moderate or mild form) who develop symptoms within the first years of life usually suffer from slight to moderate psychomotor retardation (33; 84; 38; 41; 89). There is often mild neurologic involvement with infrequent autistic features (39). Seizures were present in about 30% of these patients and were never the first sign of the mild adenylosuccinate lyase deficiency (39). Seizures, if present, appear later than in type I disease, often between the second and fourth year of life (11; 35; 89), although they may begin as late as the ninth year (25). Speech and language impairment regarding receptive and nonverbal communication skills are common (25). Progression of ataxia may cause worsening gait. Delayed motor milestones were evident in all patients, ranging from mild to moderate. Long-term follow-up of these patients showed no obvious signs of disease progression (39).

Prognosis and complications

The prognosis of adenylosuccinate lyase-deficient patients is variable. Those presenting with epilepsy in the neonatal period or early infancy may die within the first months of life. In patients with severe cognitive impairment, further evolution is characterized by stagnation or even regression of psychomotor development and persistence of autistic behavior. Patients with less severe cognitive impairment have reached adult age.

Clinical vignette

Case 1. The patient was the second daughter of unrelated Polish parents. Her older sister is healthy. Pregnancy and delivery were normal. Weight was 3550 grams, and length was 58 cm. Hypotonia was noted shortly after birth, and she had difficulty feeding. At age 7 days, she developed tonic-clonic seizures and was hospitalized. Over the following days, she had recurrent episodes of apnea and status epilepticus. She remained on artificial ventilation until her death at 2.5 months of age. Brain MRI revealed generalized atrophy of the cerebrum, an abnormally thin corpus callosum, and a generalized lack of myelination. Analysis of CSF revealed accumulation of succinylpurines, with S-Ado/SAICA-riboside ratios of 0.92. Mutation analysis on the neonatal screening card of the patient revealed compound heterozygosity for the p.Y114H and p.T242I mutations. The fatal neonatal type of adenylosuccinate lyase deficiency was diagnosed.

Case 2. The female patient was the second child of unrelated, healthy Belgian parents. Their first child was healthy. Pregnancy and delivery were normal. Weight was 3750 grams, and length was 53 cm. At age 2 years 8 months, she was admitted for evaluation of psychomotor retardation, autistic features, and failure to thrive (weight 12.4 kg, length 93 cm, head circumference 48.1 cm). Developmental age (Gesell) was 9 months for gross motor skills but 5 to 6 months for other developmental domains. Autistic behavior was striking, with impaired eye contact, repetitive manipulation of toys, grimacing, and incessant crying without apparent reason. Funduscopic examination was normal. She ground her teeth (bruxism) and bit herself. There was moderate axial hypotonia with normal tendon reflexes. Routine biochemical analyses of blood and urine and the workup for metabolic disorders were unrevealing. Auditory, somatosensory, and visual-evoked responses were normal. Nerve conduction velocities and electromyography were normal. CT and MRI of the brain showed hypoplasia of the cerebellar vermis. Analysis of urine and CSF revealed accumulation of succinylpurines, with S-Ado/SAICA-riboside ratios of 1.1 to 1.5. Adenylosuccinate lyase deficiency type I was the diagnosis.

Case 3. The female patient was the second child of unrelated Dutch parents. Neurologic impairment was first suspected during the neonatal period, and at age 2 years 11 months, she was admitted for investigation. Weight was 12 kg, but weight gain had been decelerating since the age of 2 years. Height was 93.5 cm, and head circumference was 50.5 cm. Motor development was at the level of 1.5 years, and speech development was at the level of 1 year. Eye contact was impaired, and reaction to auditory stimuli was poor, but auditory evoked potentials were normal. At the age of 3 years, EEG showed diffuse slowing without signs of epilepsy. CT and MRI of the brain showed slight cerebral hypotrophy. On re-evaluation at age 4 years, psychomotor development was at the level of 2.5 years, and EEG was "normal." Analysis of urine and CSF revealed accumulation of succinylpurines, with S-Ado/SAICA-riboside ratios of 3.7 to 4.7. Adenylosuccinate lyase deficiency type II was the diagnosis.

Biological basis

	• Adenylosuccinate lyase catalyzes two steps in the synthesis of purine nucleotides: (1) the conversion of succinyl aminoimidazole carboxamide ribotide into aminoimidazole-carboxamide ribotide, in the de novo purine synthesis pathway; and (2) the formation of adenosine monophosphate from succinyladenosine monophosphate, the second step in the conversion of inosine monophosphate to adenosine monophosphate.
	• Adenylosuccinate lyase deficiency is inherited as an autosomal recessive trait.
	• Most identified mutations are missense mutations, and most patients are compound heterozygotes.
	• Adenylosuccinate lyase deficiency causes disruption of the purinosome, a multienzyme complex of de novo purine synthesis enzymes (including adenylosuccinate lyase) that cells transiently assemble in their cytosol on depletion of, or increased demand for, purines.
	• The signs and symptoms of adenylosuccinate lyase deficiency may result from neurotoxic effects of accumulating succinylpurines.

Etiology and pathogenesis

Biochemistry. Adenylosuccinate lyase (also termed adenylosuccinase) catalyzes two steps in the synthesis of purine nucleotides: (1) the conversion of succinyl aminoimidazole carboxamide ribotide (SAICAR) into aminoimidazole-carboxamide ribotide (AICAR), in the DNPS pathway; and (2) the formation of adenosine monophosphate (AMP) from succinyladenosine monophosphate (S-AMP), the second step in the conversion of inosine monophosphate to adenosine monophosphate. Both reactions release fumarate. The term "ribotide" is a concatenation of ribonucleotide, as "ribotide" is a concatenation of ribonucleoside.

Adenylosuccinate lyase deficiency is a defect of purine metabolism that destabilizes purinosome assembly (vide infra) and reduces metabolite fluxes through both DNPS and purine nucleotide recycling pathways (07; 15).

Purine synthesis pathways

De novo synthesis involves formation, in ten steps, of inosine monophosphate from phosphoribosylpyrophosphate (PRPP). Interconversion of inosine monophosphate into guanosine monophosphate and adenosine monophosphate both occur in ...

In profoundly intellectually disabled patients with adenylosuccinate lyase deficiency, CSF concentrations of both succinylpurines are 100 to 200 µmol/l, and S-Ado/SAICA-riboside ratios are between 1 and 2. In adenylosuccinate lyase-deficient patients with milder clinical pictures, CSF concentrations of SAICA-riboside are in the same range, but those of S-Ado tend to be higher. This results in S-Ado/SAICA-riboside ratios above 2, and possibly as high as 4 to 5 (33). Urinary succinylpurine concentrations can reach 5 µmol per mg creatinine, with similar ratios to those measured from CSF. The magnitudes of S-Ado/SAICA-riboside ratios in body fluids do not predict phenotype severity, nor do they indicate inherent properties of the specific enzyme mutations, but instead reflect patient age, development, and other factors (93; 65; 66).

Individual intermediates of DNPS have potent regulatory and cytotoxic properties and, therefore, are (under physiologic conditions) either undetectable or present in very low (micromolar) concentrations in cellular extracts and body fluids (44). The efficiency of DNPS at such low concentrations of individual intermediates is ensured by the dynamic assembly and disassembly of the cytosolic multienzyme complex, the “purinosome” (03; 61). Impairment of the conversion of the two substrates of the enzyme, SAICAr and S-AMP, leads to the formation of their dephosphorylated derivatives, SAICA-ribotide and S-Ado, respectively. These metabolites accumulate in cerebrospinal fluid and urine and, to a minor extent, in plasma.

Genetics. Adenylosuccinate lyase deficiency is inherited as an autosomal recessive trait.

ADSL is transmitted as an autosomal recessive trait

(Illustration by Cburnett on March 25, 2007. Creative Commons Attribution- Share Alike 3.0 Unported license.)

In humans, the adenylosuccinate lyase (ADSL) gene spans approximately 23 kb on chromosome 22 (22q13.1q13.2) (24). It consists of 13 exons, and its promoter has the typical features of housekeeping genes. The ADSL gene is transcribed in most tissues into two transcript variants that are produced by alternative splicing of exon 12. The full-length variant encodes an active ADSL protein composed of 484 amino acids. The alternatively spliced variant encodes a catalytically inactive variant protein missing 59 amino acids (residues 397-456) (42).

Over 50 ADSL mutations have been identified in individuals with adenylosuccinate lyase deficiency. Most identified mutations are missense mutations, and most patients are compound heterozygotes (79). The most commonly identified mutation, c.1277G>A (p.Arg426His), accounts for about one third of patient alleles (14); however, there is significant phenotypic variability even among 14 reported patients homozygous for this variant (18). Many patients have private variants unique to their families. Other types of pathogenic mutations have also been identified, including splice-site mutations (94; 50) and a promoter mutation, which was found in three unrelated patients (55).

Most characterized mutations lead to structural instability of the enzyme, without modifications of its kinetic properties. The severity of the clinical symptoms correlates with residual activity of the enzyme. A R303C mutation, found in two independent, mildly cognitively impaired type II patients, is thermostable and displays markedly less activity with S-AMP than with SAICAR. This explains the markedly higher S-Ado/SAICA-ribotide ratios in type II patients (82; 64).

Purinosome. The purinosome is a multienzyme complex of the DNPS enzymes (including adenylosuccinate lyase) that cells transiently assemble in their cytosol on depletion of, or increased demand for, purines (03).

Studies of purinosome formation in skin fibroblasts of patients with adenylosuccinate lyase deficiency showed considerable interindividual variation in purinosome assembly, with the ability to form purinosomes inversely associated with phenotype severity (07). Studies utilizing CRISPR-Cas9 editing of HeLa cells confirmed that purinosome formation is disrupted in adenylosuccinate lyase deficiency (06). The phenotypic severity of adenylosuccinate lyase deficiency and formation and stability of the purinosome are mainly determined by the structural stability and residual catalytic capacity of the corresponding mutant adenylosuccinate lyase protein complex (93; 87).

Pathophysiologic mechanisms. Hypotheses regarding the pathogenesis of adenylosuccinate lyase deficiency include toxicity of high levels of SAICAR, S-AMP, or their metabolites, deficiency of purine synthesis through the DNPS pathway, or disruption of the purine cycle in muscle and brain (40).

Possible toxic effects of intermediates. The signs and symptoms of adenylosuccinate lyase deficiency may result from neurotoxic effects of accumulating succinylpurines. Less severe intellectual impairment in patients with similar SAICA-riboside levels, but S-Ado/SAICA-riboside ratios above 2, might suggest that SAICA-riboside is the offending neurotoxic compound and that S-Ado could protect against the toxic effects of SAICA-riboside. However, when the activity of the enzyme against both substrates was measured separately (noncompetitively), patients exhibited a proportional decrease in enzyme activity against both substrates (42). When both substrates were present and competing against each other for the same residual enzyme activity, S-Ado/SAICA-riboside ratios varied as a function of the specific mutations (66). Alternatively, the observed abnormal ratios might be explained by differential transport of these succinylpurines across membranes (42); for example, it is known that SAICA-riboside is transported by ABCC5 (34).

Attempts to demonstrate neurotoxicity of the succinylpurines have failed, with very limited exceptions: (1) infusion of SAICAr (SAICA-riboside) to rats induced neuronal damage in specific regions of the hippocampus, consistent with the hypothesis that SAICAr is neurotoxic (77); (2) accumulation of SAICAr in a C. elegans model of adenylosuccinate lyase deficiency altered cholinergic neurotransmission (22). Although S-Ado and SAICAr are analogs of adenosine and glutamate, they neither modify the CNS effects of adenosine nor disrupt glutamatergic neurotransmission (78).

Curiously, HeLa cells with adenylosuccinate lyase deficiency (induced via CRISPR-Cas9) accumulate AICAR (06), which is quite puzzling, given that AICAR is a metabolite distal to the enzymatic block. AICAR might be provided via an alternative histidine biosynthesis pathway, which is known to crosstalk with the DNPS pathway in yeast (67); however, no pathway for histidine biosynthesis is known in humans.

Deficiency of purine nucleotides. Deficient DNPS caused by adenylosuccinate lyase deficiency has been thought to have detrimental effects during embryonic development. However, normal levels of purines were measured in various tissues of affected patients (85), presumably because of residual (partial) activity of adenylosuccinate lyase (31; 33) and additional supply of purines through the purine salvage pathway, involving the enzymes hypoxanthine-guanine phosphoribosyltransferase, adenine phosphoribosyltransferase, and adenosine kinase. Curiously, a worm model of disease utilizing a double knockout of adenylosuccinate lyase and the enzyme just proximal to it in the DNPS pathway leads to a masking of the phenotype (13); consequently, these authors have advocated blockage of this proximal enzyme as a potential therapeutic approach. Nevertheless, a deficiency of purine nucleotides could potentially occur in some cell types with profound deficiency of adenylosuccinate lyase and low activity of the salvage pathway. Similarly, the expression of a trifunctional protein participating in DNPS is known to be 20 times higher in human prenatal than in postnatal cerebellum (09), and the degree of DNPS is also known to decrease dramatically after birth in rat brains (01; 02). Little is known about the actual purine levels in the living brain or about the regulation of purine synthesis during embryogenesis, both of which might be affected by defects in purine metabolism (40).

Impairment of energy metabolism. Adenylosuccinate lyase participates in the purine nucleotide cycle along with adenosine monophosphate deaminase and adenylosuccinate synthetase, and disruption of this cycle in adenylosuccinate lyase deficiency has been suggested to cause the disorder. The purine nucleotide cycle controls the levels of fumarate, a Krebs cycle intermediate, and of adenosine monophosphate, needed particularly for maintaining the ATP/AMP ratio in muscles (84).

Animal models. Cellular and nematode models of adenylosuccinate lyase deficiency could lead to an improved understanding of the disease and subsequent development of effective treatment (87; 13; 22; 59).

Homozygous knockout of the mouse adenylosuccinate lyase ortholog is lethal prior to weaning (16).

A Caenorhabditis elegans model of adenylosuccinate lyase deficiency has been developed (22; 59). The lack of fertility in a roundworm model of the disease resulted from reduced DNPS, even though there was no significant decrease in purine metabolite concentrations (22). In this model, adenylosuccinate lyase function contributes to regulation of spontaneous locomotion, and aspects of adenylosuccinate lyase-related dysfunction are reversible (22). Differing molecular mechanisms are responsible for the different phenotypes: the neuromuscular defect correlates with accumulation of a purine biosynthetic intermediate whereas reproductive deficiencies can be ameliorated by purine supplementation (22). Learning is also affected as demonstrated with a gustatory plasticity assay (59). The worms maintain capacity for gustatory plasticity a demonstrated by a behavioral change in response to cue pairing, although their behavior is distinct from that of control animals. Substrate accumulation is associated with an unexpected perturbation in tyrosine metabolism: a lack of tyramine mediates the behavioral changes through action on the metabotropic TYRA-2 tyramine receptor.

Multiple phenotypes associated with adenylosuccinate lyase depletion in developing chicken and zebrafish embryos can largely be rescued by interventions that suppress the generation of metabolites in the DNPS pathway or restore purine levels, thereby complementing defective DNPS or purine nucleotide pathway activity; thus, both reduced purine levels and impaired DNPS contribute to neurodevelopmental pathology in adenylosuccinate lyase deficiency (19).

Differential diagnosis

Confusing conditions

Adenylosuccinate lyase deficiency should be distinguished from (1) other neurologic disorders with intractable seizures and encephalopathy and (2) other inborn errors of purine and pyrimidine metabolism with neurologic manifestations.

Other disorders presenting predominantly with intractable seizures include the following:

	• Angelman syndrome (OMIM 105830) • Fumarase deficiency (FH, OMIM 606812) • Biotin-responsive holocarboxylase synthetase deficiency (HLCS, OMIM 253270) • Biotin-responsive biotinidase deficiency (BTD, OMIM 253260) • GLUT1 deficiency (SLC2A1, OMIM 606777) • Glycine encephalopathy/nonketotic hyperglycinemia (GAMT, GLDC, GCSH, OMIM 605899) • D-2-hydroxyglutaric aciduria (D2HGDH, OMIM 600721; IDH2, OMIM 613657) • Mitochondrial glutamate transporter deficiency or early infantile epileptic encephalopathy 3 (SLC25A22, OMIM 609304) • Mitochondrial respiratory chain disorders • Molybdenum cofactor deficiency (sulfite oxidase/xanthine oxidase/aldehyde oxidase deficiency, MOCS1, MOCS2, GPHN, OMIM 252150)
		- Isolated sulfite oxidase deficiency (SUOX, OMIM 272300)
	• Menkes disease (ATP7A, OMIM 309400) • Peroxisomal biogenesis defects (Zellweger syndrome, ZS, OMIM 214100) • 3-phosphoglycerate dehydrogenase deficiency (PHGDH, OMIM 601815) • Pyridoxine-dependent epilepsies (ALDH7A1, OMIM 266100; PROSC, OMIM 617290) • Pyridox(am)ine-5'-phosphate oxidase deficiency (PNPO, OMIM 610090)

Other inborn errors of purine and pyrimidine metabolism with neurologic manifestations include the following:

	• AICA-ribosuria due to ATIC deficiency (ATIC, OMIM 608688) • Dihydropyrimidinase deficiency (DPYS, OMIM 222748) • Hypoxanthine-guanine phosphoribosyltransferase deficiency 1 (HPRT1, OMIM 308000):
		- Lesch-Nyhan disease (OMIM 300322) - HPRT-related hyperuricemia (OMIM 300323)
	• Molybdenum cofactor deficiency (MOCS1, OMIM 252150; MOCS2, OMIM 603708; GPHN, OMIM 615501) • Purine nucleoside phosphorylase deficiency (PNP, OMIM 613179) • Phosphoribosyl-pyrophosphate synthase superactivity (PRPS1, OMIM 300661) • CAD trifunctional protein deficiency/uridine-responsive epileptic encephalopathy (CAD, 616457) • Uridine monophosphate synthase deficiency (UMPS, OMIM 613891) • Beta-ureidopropionase deficiency (UPB1, OMIM 613161)

The wide clinical spectrum of the disease accounts for possible difficulties in differential diagnosis with neurologic disorders, especially those with intractable seizures and encephalopathy.

In the neonatal period, the differential diagnosis should include particularly the five treatable disorders that can present with intractable seizures in neonates: (1) pyridoxine-dependent epilepsy, (2) pyridox(am)ine-5'-phosphate oxidase deficiency, (3) folinic acid-responsive seizures, (4) 3-phosphoglycerate dehydrogenase deficiency, and (5) hyperinsulinemic hypoglycemia (71). Biotin-responsive holocarboxylase synthetase deficiency can also rarely present with neonatal seizures. In the first months of life, biotin-responsive biotinidase deficiency and GLUT1 deficiency (which is treated with the ketogenic diet) can also present with intractable seizures. Other inborn errors of metabolism less amenable to treatment can present in the neonatal period with severe epilepsy, including nonketotic hyperglycinemia, D-2-hydroxyglutaric aciduria, mitochondrial glutamate transporter defect, peroxisomal biogenesis defects, respiratory chain disorders, molybdenum cofactor and isolated sulfite oxidase deficiency, and Menkes disease. In infancy, the association of seizures and autistic features should prompt consideration of Angelman syndrome and Rett syndrome.

SAICAr and S-Ado elevations also occur in two other conditions: AICA-ribosuria (AICAR transformylase/inosine monophosphate cyclohydrolase deficiency) and, to a lesser degree, fumarase deficiency. One patient has been reported with AICA-ribosuria--a female infant with dysmorphic features, severe neurologic defects, and congenital blindness. She had significant elevations of SAICAr and S-Ado detectable in urine and CSF. In contrast to adenylosuccinate lyase deficiency, these findings were associated with massive excretion of AICA-riboside (AICAr), the dephosphorylated counterpart of AICAR, one of the products of adenylosuccinate lyase (54). Further studies led to the identification of a deficiency of the bifunctional enzyme that catalyzes the final steps of purine biosynthesis AICAR transformylase/inosine monophosphate cyclohydrolase (ATIC).

Fumarase deficiency has been associated with less pronounced elevations of succinylpurines in one patient who had dysmorphic features, brain malformations, severe developmental delay with progressive hypotonia, hepatosplenomegaly, and neutropenia (91). S-Ado (8.4 umol/l) and SAICAr (7.6 umol/l) were detected in CSF but not in urine, likely due to dilution below the detection limit of the test. These succinylpurine levels were clearly abnormal, with S-Ado six times the upper limit of the reference range but lower than the 100 to 200 umol/l concentrations typical for adenylosuccinate lyase deficiency. Succinylpurine elevations in fumarase deficiency are thought to reflect inhibition of adenylosuccinate lyase by excessive fumarate because fumarate is the first product released in both of the adenylosuccinate lyase-catalyzed reactions and acts as a weak inhibitor of this enzyme in vitro. The authors suggested that an accumulation of succinylpurines in the CNS might contribute to the pathogenesis of fumarase deficiency (91).

Diagnostic workup

	• Head-imaging abnormalities include atrophy of the cerebral cortex, corpus callosum, and cerebellar vermis; delayed or lack of myelination; anomalies of the white matter; and lissencephaly.
	• The combination of hypomyelination with psychomotor retardation should raise suspicion of this disorder in children with consistent clinical features.
	• Biochemical diagnosis requires demonstration of succinyl aminoimidazole carboxamide riboside (SAICAr) and succinyladenosine (S-Ado) in extracellular fluids, such as plasma, cerebrospinal fluid, or urine, using HPLC with UV detection or HPLC-MS.
	• Genetic diagnosis requires mutation analysis, specifically the genomic or cDNA sequencing of adenylosuccinate lyase gene and characterization of mutant proteins.
	• Diagnosis is supported by (1) evidence of an appropriate clinical phenotype; (2) demonstration of SAICAr and S-Ado in extracellular fluids, such as urine, CSF, or plasma; and (3) confirmation at an accredited laboratory of large decrease of adenylosuccinate lyase enzyme activity in cultured skin fibroblasts.

Neuroimaging. Head-imaging abnormalities include atrophy of the cerebral cortex (with frontal predominance), corpus callosum, and cerebellar vermis; delayed or lack of myelination; anomalies of the white matter; and lissencephaly (80; 43; 62; 75; 20; 56; 48; 36; 14). The combination of hypomyelination with psychomotor retardation should raise suspicion of this disorder in children with consistent clinical features. Diffusion restriction may be present in bilateral basal ganglia, thalamus, and periventricular white matter (05).

Magnetic resonance spectroscopy of white matter abnormalities can suggest adenylosuccinate lyase deficiency if specific metabolites are detected but has not been tested sufficiently to rule out the diagnosis. In patients with white matter abnormalities on MRI, proton magnetic resonance spectroscopy may help suggest the diagnosis as the abnormal-appearing areas may contain abnormal peaks corresponding to S-Ado at 8.3 ppm and SAICAR at 7.5 ppm (27; 94). However, these metabolite peaks typically fall outside of the usual chemical shift range evaluated during clinical neuroimaging procedures (0 to 4 ppm).

Electroencephalography. Common patterns of electroencephalographic abnormalities and developmental trajectories include the following: (1) poor general background organization with theta-delta activity; (2) hypsarrhythmia with infantile spasms (usually adrenocorticotropic hormone-responsive); (3) generalized epileptic discharges with frontal or frontotemporal predominance; and (4) epileptic discharge activation in sleep with an altered sleep structure (14).

Biochemical and genetic diagnosis. Biochemical and genetic diagnosis requires the following (40):

	• Demonstration of succinyl aminoimidazole carboxamide riboside (SAICAr) and succinyladenosine (S-Ado) in extracellular fluids, such as plasma, cerebrospinal fluid, or urine, using HPLC with UV detection or HPLC-MS
	• Mutation analysis--genomic or cDNA sequencing of adenylosuccinate lyase gene and characterization of mutant proteins

Diagnosis is supported by the following (40):

	• Evidence of an appropriate clinical phenotype
	• Demonstration of SAICAr and S-Ado in extracellular fluids, such as urine, CSF, or plasma, using simple screening tests, such as Bratton-Marshall or thin-layer chromatography
	• Analysis of adenylosuccinate lyase enzyme activity in cultured skin fibroblasts at an accredited laboratory to demonstrate a large decrease of adenylosuccinate lyase activity. Although adenylosuccinate lyase enzyme activity levels may differ between testing laboratories, enzyme activity in patients with adenylosuccinate lyase is generally between 2% and 20% of the lower limit of normal (68). Enzyme assay in lysates is not completely reliable due to tissue heterogeneity of the adenylosuccinate lyase defect (60).

Biochemical diagnostic methods. The deficiency of adenylosuccinate lyase activity results in the accumulation of SAICAR and S-AMP in the cells and the presence of enormously elevated concentrations of their dephosphorylated forms, SAICA-riboside (SAICAr) and S-Ado in extracellular fluids--urine and CSF and, to a lesser extent, also in plasma (40). SAICAr and S-Ado are present in low micromolar concentrations in bodily fluids of controls (72; 44). In patients with adenylosuccinate lyase deficiency, concentrations of both metabolites range from 5 to 10 µmol/L in plasma, 100 to 200 µmol/L in CSF, and in the millimolar range in urine (31). Several methods have been described for selective screening of subjects with adenylosuccinate lyase deficiency that allow identification of either one or two of the relevant compounds in body fluids.

The preferred diagnostic methods are HPLC-DAD or LC-MS/MS because these allow detection of both SAICAr and S-Ado and their deribosylation products (46; 40). In particular, high-throughput urine screening techniques for adenylosuccinate lyase deficiency have been developed using HPLC combined with electrospray ionization tandem mass spectrometry (MS/MS) (30; 26; 86). These methods allow rapid and specific screening for disorders of purine and pyrimidine metabolism with use of liquid urine samples or urine-soaked filter-paper strips. A similar LC-MS/MS-based assay for dried blood spots has also been described (92).

Other methods used include a modified Bratton-Marshall test (47); thin-layer chromatography for identification of SAICAr (88), S-Ado (51) and both nucleosides (32); isolation of SAICAr and S-Ado with a cation exchange resin and determination of A270/A250 ratio (UV absorbance of the ammonia eluate at 270 and 250 nm) (17); capillary electrophoresis (29); and high-resolution proton magnetic resonance spectroscopy (27). However, although the Bratton-Marshall test and thin-layer chromatography with Pauly reagent detect excessive urinary SAICAr, false-negative results have been reported due to bacteria-mediated deribosylation of SAICAr and S-Ado in urine (46). In addition, because the Bratton-Marshall test detects free primary aromatic amines, false-positive results may be observed in patients who receive antibiotics, such as sulfonamides (for which the test was initially devised), anticonvulsants (including clonazepam, nitrazepam, and lamotrigine), or other medications that contain or have metabolites containing this group.

Enzymatic diagnosis of adenylosuccinate lyase deficiency is possible in liver biopsy specimens, preferably fresh tissue, because the enzyme is unstable to freezing and thawing (81). Cultured skin fibroblasts are less appropriate for diagnosis because adenylosuccinate lyase activity is variable in this tissue and only partially deficient in affected patients.

Prenatal diagnosis is limited to families having a previous child with adenylosuccinate lyase deficiency and is based on mutational analysis for at-risk fetuses. Diagnostic testing may be conducted for prenatal diagnosis on viable fetal cells from chorionic villi, cultured amniotic fluid cells, or in the newborn dried blood spots (53).

Selective screening for adenylosuccinate lyase deficiency. The wide clinical spectrum of adenylosuccinate lyase deficiency complicates the differential diagnosis with other neurologic disorders, especially those with intractable seizures and encephalopathy (10; 40). Therefore, when adenylosuccinate lyase deficiency is possible or suspected, diagnostic protocols are needed to avoid useless investigations and treatments. The marked clinical heterogeneity justifies systemic screening for the disorder in patients with the following symptoms (40):

	• Newborns and infants with hypotonia and acquired microcephaly
	• Unexplained psychomotor retardation
	• Unexplained developmental delay
	• Unexplained seizures, especially intractable
	• MRI findings such as atrophy of the cerebral cortex, corpus callosum, cerebellar vermis, lack of myelination, delayed myelination, anomalies of the white matter

Management

	• No specific FDA-approved treatment is available for adenylosuccinate lyase deficiency.
	• Several supplements have been used empirically in a small number of patients, all aimed at replenishing hypothetically deficient adenine nucleotides in adenylosuccinate lyase-deficient tissues, but none of them has shown any clear benefit.
	• Seizure management in adenylosuccinate lyase deficiency utilizes standard anticonvulsants.
	• Use of the ketogenic diet may be helpful for patients with intractable epilepsy.

No specific FDA-approved treatment is available for adenylosuccinate lyase deficiency.

Several supplements have been used empirically in a small number of patients, all aimed at replenishing hypothetically deficient adenine nucleotides in adenylosuccinate lyase-deficient tissues, but none of them has shown any clear benefit (33; 70; 69; 38; 41; 63; 86; 52). These include trials of 3 months to as many as 20 months with oral supplements of adenine and allopurinol (the latter to avoid conversion by xanthine oxidase of adenine into poorly soluble 2,8-dihydroxyadenine) (33), D-ribose and uridine (70; 69), D-ribose alone (38; 41; 63; 52), and S-adenosylmethionine, (which can enter the CNS) (86). Urine succinylpurines were also unchanged, suggesting that treatment did not lead to feedback inhibition of DNPS. It is unclear if the negative results of purine supplementation are due to unaddressed neurotoxicity of accumulating metabolites.

Seizure management in adenylosuccinate lyase deficiency utilizes standard anticonvulsants. Myoclonic seizures have been treated with valproic acid in combination with other drugs, such as clobazam and levetiracetam (50; 52). Infantile spasms may be resistant to treatment (48; 94). However, patients have had cessation of spasms with therapies including high-dose prednisolone (90) and vigabatrin, which normalized EEG in one patient (86; 58), although they subsequently developed other types of seizures.

Use of the ketogenic diet for intractable epilepsy has been reported in five patients with adenylosuccinate lyase deficiency, four of whom had some improvement in seizure control. One patient with neonatal-onset epilepsy was seizure-free on the ketogenic diet from ages 2 to 5 years but developed a metabolic hyperchloremic acidosis with Fanconi syndrome, which resolved a month after cessation of the diet (37). A patient with infantile spasms did not respond to the ketogenic diet (94). Another patient with generalized tonic and clonic seizures had a 95% reduction in seizure frequency when the ketogenic diet was started at 7 years of age, with 2 years of follow-up (39). Finally, a pair of monozygotic twins with neonatal onset of seizures started on the ketogenic diet at 3 months of age and had 14 months of seizure freedom, even with no other anticonvulsants, although seizures subsequently recurred (52). One patient also had improvement of nonepileptic paroxysmal dyskinesias and dystonias on the ketogenic diet (08).

Media

References

01: Allsop J, Watts RW. Purine de novo synthesis in liver and developing rat brain, and the effect of some inhibitors of purine nucleotide interconversion. Enzyme 1983;30(3):172-80. PMID 6628351
02: Allsop J, Watts RW. Purine synthesis and salvage in brain and liver. In: De Bruyn CH, Simmonds HA, Müller MM, editors. Purine Metabolism in Man-IV. Vol 165. Advances in Experimental Medicine and Biology. Springer: Boston, MA, 1984.
03: An S, Kumar R, Sheets ED, Benkovic SJ. Reversible compartmentalization of de novo purine biosynthetic complexes in living cells. Science 2008;320(5872):103-6. PMID 18388293
04: Andelman-Gur MM, Saitsu H, Matsumoto N, et al. Myoclonic tremor status as a presenting symptom of adenylosuccinate lyase deficiency. Eur J Med Genet 2020;63(12):104061. PMID 32890691
05: Banerjee A, Bhatia V, Didwal G, Singh AK, Saini AG. ADSL deficiency - the lesser-known metabolic epilepsy in infancy. Indian J Pediatr 2021;88(3):263-5. PMID 32681428
06: Baresova V, Krijt M, Skopova V, Souckova O, Kmoch S, Zikanova M. CRISPR-Cas9 induced mutations along de novo purine synthesis in HeLa cells result in accumulation of individual enzyme substrates and affect purinosome formation. Mol Genet Metab 2016;119(3):270-7. PMID 27590927
07: Baresova V, Skopova V, Sikora J, et al. Mutations of ATIC and ADSL affect purinosome assembly in cultured skin fibroblasts from patients with AICA-ribosiduria and ADSL deficiency. Hum Mol Genet 2012;21(7):1534-43. PMID 22180458
08: Blumkin L, Saitsu H, Matsumoto N, et al. P147-2569: adenylosuccinate lyase deficiency presenting as a paroxysmal movement disorder. Eur J Paediatr Neurol 2015;19(S1):S135.
09: Brodsky G, Barnes T, Bleskan J, Becker L, Cox M, Patterson D. The human GARS-AIRS-GART gene encodes two proteins which are differentially expressed during human brain development and temporally overexpressed in cerebellum of individuals with Down syndrome. Hum Mol Genet 1997;6(12):2043-50. PMID 9328467
10: Castro M, Carrillo R, García F, et al. Thirteen years experience with selective screening for disorders in purine and pyrimidine metabolism. Nucleosides Nucleotides Nucleic Acids 2014;33(4-6):233-40. PMID 24940674
11: Castro M, Perez-Cerda C, Merinero B, et al. Screening for adenylosuccinate lyase deficiency: clinical, biochemical and molecular findings in four patients. Neuropediatrics 2002;33(4):186-9. PMID 12368987
12: Chen BC, McGown IN, Thong MK, et al. Adenylosuccinate lyase deficiency in a Malaysian patient with novel adenylosuccinate lyase gene mutations. J Inherit Metab Dis 2010;33 Suppl 3:S159-62. PMID 20177786
13: Chen P, Wang D, Chen H, Zhou Z, He X. The nonessentiality of essential genes in yeast provides therapeutic insights into a human disease. Genome Res 2016;26(10):1355-62. PMID 27440870
14: Cutillo G, Masnada S, Lesca G, et al. Electroclinical features and phenotypic differences in adenylosuccinate lyase deficiency: Long-term follow-up of seven patients from four families and appraisal of the literature. Epilepsia Open 2024;9(1):106-21. PMID 37842880
15: Dewulf JP, Marie S, Nassogne MC. Disorders of purine biosynthesis metabolism. Mol Genet Metab 2022;136(3):190-8. PMID 34998670
16: Dickinson ME, Flenniken AM, Ji X, et al. High-throughput discovery of novel developmental phenotypes. Nature 2016;537(7621):508-14. PMID 27626380
17: Domkin VD, Lazebnik TA, Roudneff AYu, Smirnov MN. A new diagnostic technique for adenylosuccinate lyase deficiency. J Inherit Metab Dis 1995;18(3):291-4. PMID 7474894
18: Donti TR, Cappuccio G, Hubert L. Diagnosis of adenylosuccinate lyase deficiency by metabolomic profiling in plasma reveals a phenotypic spectrum. Mol Genet Metab Rep 2016;8:61-6. PMID 27504266
19: Dutto I, Gerhards J, Herrera A, et al. Pathway-specific effects of ADSL deficiency on neurodevelopment. Elife 2022;11:e70518. PMID 35133277
20: Edery P, Chabrier S, Ceballos-Picot I, Marie S, Vincent MF, Tardieu M. Intrafamilial variability in the phenotypic expression of adenylosuccinate lyase deficiency: a report on three patients. Am J Med Genet A 2003;120A(2):185-90. PMID 12833398
21: Fechete I. Hermann Emil Fischer--the most outstanding chemist in history. Comptes Rendus Chimie 2016;19:1143-9.
22: Fenton AR, Janowitz HN, Franklin LP, et al. A Caenorhabditis elegans model of adenylosuccinate lyase deficiency reveals neuromuscular and reproductive phenotypes of distinct etiology. Mol Genet Metab 2023;140(3):107686. PMID 37607437
23: Ferreira CR. Prevalence of adenylosuccinate lyase deficiency based on aggregated exome data. Mol Genet Metab Rep 2017;10:81-2. PMID 28127531
24: Fon EA, Demczuk S, Delattre O, Thomas G, Rouleau GA. Mapping of the human adenylosuccinate lyase (ADSL) gene to chromosome 22q13.1-->q13.2. Cytogenet Cell Genet 1993;64(3-4):201-3. PMID 8404037
25: Gitiaux C, Ceballos-Picot I, Marie S, et al. Misleading behavioural phenotype with adenylosuccinate lyase deficiency. Eur J Hum Genet 2009;17(1):133-6. PMID 18830228
26: Hartmann S, Okun JG, Schmidt C, et al. Comprehensive detection of disorders of purine and pyrimidine metabolism by HPLC with electrospray ionization tandem mass spectrometry. Clin Chem 2006;52(6):1127-37. PMID 16613999
27: Henneke M, Dreha-Kulaczewski S, Brockmann K, et al. In vivo proton MR spectroscopy findings specific for adenylosuccinate lyase deficiency. NMR Biomed 2010;23(5):441-5. PMID 20175147
28: Holder-Espinasse M, Marie S, Bourrouillou G, et al. Towards a suggestive facial dysmorphism in adenylosuccinate lyase deficiency. J Med Genet 2002;39(6):440-2. PMID 12070256
29: Hornik P, Vyskocilova P, Friedecky D, Janostakova A, Adamova K, Adam T. Analysis of aminoimidazole ribosides by capillary electrophoresis—diagnosing defects in second part of purine biosynthetic pathway. Clin Chim Acta 2007;376(1-2):184-9. PMID 17010959
30: Ito T, van Kuilenburg AB, Bootsma AH, et al. The application of HPLC/ESI tandem mass spectrometry on urine-soaked filter-paper strips for the screening of disorders of purine and pyrimidine metabolism. J Inherit Metab Dis 2000;23(4): 434-7. PMID 10896312
31: Jaeken J, Van den Berghe G. An infantile autistic syndrome characterised by the presence of succinylpurines in body fluids. Lancet 1984;2(8411):1058-61. PMID 6150139
32: Jaeken J, van den Berghe G. Screening for inborn errors of purine synthesis. Lancet 1989;1(8636):500. PMID 2563871
33: Jaeken J, Wadman SK, Duran M, et al. Adenylosuccinase deficiency: an inborn error of purine nucleotide synthesis. Eur J Pediatr 1988;148(2):126-31. PMID 3234432
34: Jansen RS, Mahakena S, de Haas M, Borst P, van de Wetering K. ATP-binding cassette subfamily C member 5 (ABCC5) functions as an efflux transporter of glutamate conjugates and analogs. J Biol Chem 2015;290(51):30429-40. PMID 26515061
35: Jurecka A. Inborn error of purine and pyrimidine metabolism. J Inherit Metab Dis 2009;32(2):247-63. PMID 19291420
36: Jurecka A, Jurkiewicz E, Tylki-Szymanska A. Magnetic resonance imaging of the brain in adenylosuccinate lyase deficiency: a report of seven cases and a review of the literature. Eur J Pediatr 2012a;171(1):131-8. PMID 21625931
37: Jurecka A, Opoka-Winiarska V, Rokicki D, Tylki-Szymańska A. Neurologic presentation, diagnostics, and therapeutic insights in a severe case of adenylosuccinate lyase deficiency. J Child Neurol 2012b;27(5):645-9. PMID 22140128
38: Jurecka A, Tylki-Szymanska A, Zikanova M, et al. D-Ribose therapy in four Polish patients with adenylosuccinate lyase deficiency: absence of positive effect. J Inherit Metab Dis 2008a;31(6):548. PMID 18649008
39: Jurecka A, Zikanova M, Jurkiewicz E, Tylki-Szymanska A. Attenuated adenylosuccinate lyase deficiency: a report of one case and a review of the literature. Neuropediatrics 2014;45(1):50-5. PMID 23504561
40: Jurecka A, Zikanova M, Kmoch S, Tylki-Szymańska A. Adenylosuccinate lyase deficiency. J Inherit Metab Dis 2015;38(2):231-42.** PMID 25112391
41: Jurecka A, Zikanova M, Tylki-Szymanska A, et al. Clinical, biochemical and molecular findings in seven Polish patients with adenylosuccinate lyase deficiency. Mol Genet Metab 2008b;94(4):435-42. PMID 18524658
42: Kmoch S, Hartmannova H, Stiburkova B, Krijt J, Zikanova M, Sebesta I. Human adenylosuccinate lyase (ADSL), cloning and characterization of full-length cDNA and its isoform, gene structure and molecular basis for ADSL deficiency in six patients. Hum Mol Genet 2000;9(10):1501-13. PMID 10888601
43: Kohler M, Assmann B, Brautigam C, et al. Adenylosuccinase deficiency: possibly underdiagnosed encephalopathy with variable clinical features. Eur J Pediatr Neurol 1999;3(1):3-6.
44: Krijt J, Kmoch S, Hartmannova H, Havlicek V, Sebesta I. Identification and determination of succinyladenosine in human cerebrospinal fluid. J Chromatogr B Biomed Sci Appl 1999;726(1-2):53-8. PMID 10348170
45: Krijt J, Sebesta I, Svehlakova A, Zumrova A, Zeman J. Adenylosuccinate lyase deficiency in a Czech girl and two siblings. Adv Exp Med Biol 1994;370:367-70. PMID 7660930
46: Krijt J, Skopova V, Adamkova V, et al. The need for vigilance: false-negative screening for adenylosuccinate lyase deficiency caused by deribosylation of urinary biomarkers. Clin Biochem 2013;46(18):1899-901. PMID 24183879
47: Laikind PK, Seegmiller JE, Gruber HE. Detection of 5’-phosphoribosyl-4-(N-succinylcarboxamide)-5-aminoimidazole in urine by use of the Bratton-Marshall reaction: Identification of patients deficient in adenylosuccinate lyase activity. Anal Biochem 1986;156(1):81-90. PMID 3740420
48: Lundy CT, Jungbluth H, Pohl KR, et al. Adenylosuccinate lyase deficiency in the United Kingdom pediatric population: first three cases. Pediatr Neurol 2010;43(5):351-4. PMID 20933180
49: Maaswinkel-Mooij PD, Laan LA, Onkenhout W, Brouwer OF, Jaeken J, Poorthuis BJ. Adenylosuccinase deficiency presenting with epilepsy in early infancy. J Inherit Metab Dis 1997;20(4):606-7. PMID 9266401
50: Macchiaiolo M, Barresi S, Cecconi F, et al. A mild form of adenylosuccinate lyase deficiency in absence of typical brain MRI features diagnosed by whole exome sequencing. Ital J Pediatr 2017;43(1):65. PMID 28768552
51: Maddocks J, Reed T. Urine test for adenylosuccinase deficiency in autistic children. Lancet 1989;1(8630):158-9. PMID 2563072
52: Mao X, Li K, Tang B, et al. Novel mutations in ADSL for Adenylosuccinate Lyase Deficiency identified by the combination of Trio-WES and constantly updated guidelines. Sci Rep 2017;7(1):1625. PMID 28487569
53: Marie S, Flipsen JW, Duran M, et al. Prenatal diagnosis in adenylosuccinate lyase deficiency. Prenat Diagn 2000;20(1):33-6. PMID 10701848
54: Marie S, Heron B, Bitoun P, Timmerman T, Van den Berghe G, Vincent MF. AICA-ribosiduria: a novel, neurologically devastating inborn error of purine biosynthesis caused by mutation of ATIC. Am J Hum Genet 2004; 74(6):1276-81. PMID 15114530
55: Marie S, Race V, Nassogne MC, Vincent MF, Van den Berghe G. Mutation of a nuclear respiratory factor 2 binding site in the 5’ untranslated region of the ADSL gene in three patients with adenylosuccinate lyase deficiency. Am J Hum Genet 2002;71(1):14-21. PMID 12016589
56: Marinaki A, Champion M, Kurian MA, et al. Adenylosuccinate lyase deficiency--First British case. Nucleosides Nucleotides Nucleic Acids 2004;(8-9):1231-3. PMID 15571235
57: Mastrogiorgio G, Macchiaiolo M, Buonuomo PS, et al. Clinical and molecular characterization of patients with adenylosuccinate lyase deficiency. Orphanet J Rare Dis 2021;16(1):112. PMID 33648541
58: Michaud JL, Lachance M, Hamdan FF, et al. The genetic landscape of infantile spasms. Hum Mol Genet 2014;23(18):4846-58. PMID 24781210
59: Moro CA, Sony SA, Franklin LP, et al. Adenylosuccinate lyase deficiency affects neurobehavior via perturbations to tyramine signaling in Caenorhabditis elegans. PLoS Genet 2023;19(9):e1010974. PMID 37773959
60: Mouchegh K, Zikanova M, Hoffmann GF, et al. Lethal fetal and early neonatal presentation of adenylosuccinate lyase deficiency: observation of 6 patients in 4 families. J Pediatr 2007;150(1):57-61.e2.
61: Narayanaswamy R, Levy M, Tsechansky M, et al. Widespread reorganization of metabolic enzymes into reversible assemblies upon nutrient starvation. Proc Natl Acad Sci USA 2009;106(25):10147-52. PMID 19502427
62: Nassogne MC, Henrot B, Aubert G, et al. Adenylosuccinase deficiency: an unusual cause of early-onset epilepsy associated with acquired microcephaly. Brain Dev 2000;22(6):383-6.
63: Perez-Duenas B, Sempere A, Campistol J, et al. Novel features in the evolution of adenylosuccinate lyase deficiency. Eur J Paediatr Neurol 2012;16(4):343-8. PMID 21903433
64: Race V, Marie S, Vincent MF, Van den Berghe G. Clinical, biochemical and molecular genetic correlations in adenylosuccinate lyase deficiency. Hum Mol Genet 2000;9(14):2159-65. PMID 10958654
65: Ray SP, Deaton MK, Capodagli GC, et al. Structural and biochemical characterization of human adenylosuccinate lyase (ADSL) and the R303C ADSL deficiency-associated mutation. Biochemistry 2012;51(33):6701-13. PMID 22812634
66: Ray SP, Duval N, Wilkinson TG 2nd, Shaheen SE, Ghosh K, Patterson D. Inherent properties of adenylosuccinate lyase could explain S-Ado/SAICAr ratio due to homozygous R426H and R303C mutations. Biochim Biophys Acta 2013;1834(8):1545-53. PMID 23714113
67: Rebora K, Laloo B, Daignan-Fornier B. Revisiting purine-histidine cross-pathway regulation in Saccharomyces cerevisiae: a central role for a small molecule. Genetics 2005;170(1):61-70. PMID 15744050
68: Salerno C. Crifo C. Microassay of adenylosuccinase by capillary electrophoresis. Anal Biochem 1995;226(2):377-9. PMID 7793642
69: Salerno C, Crifo C, Curatolo P, Ciardo F. Effect of uridine administration to a patient with adenylosuccinate lyase deficiency. Adv Exp Med Biol 2000;486:75-8. PMID 11783531
70: Salerno C, D’Eufemia P, Finocchiaro R, et al. Effect of D-ribose on purine synthesis and neurological symptoms in a patient with adenylosuccinase deficiency. Biochim Biophys Acta 1999;1453(1):135-40. PMID 9989253
71: Saudubray JM, Desguerre I, Sedel F, Charpentier C. A clinical approach to inherited metabolic disease. In: Fernandes J, Saudubray J-M, van den Berghe G, Walter JH, editors. Inborn metabolic diseases - Diagnosis and treatment. 4th ed. Heidelberg: Springer, 2006:3-48.
72: Sebesta I, Krijt J, Kmoch S, Hartmannova H, Wojda M, Zeman J. Adenylosuccinase deficiency: clinical and biochemical findings in 5 Czech patients. J Inherit Metab Dis 1997;20(3):343-34. PMID 9266351
73: Sitaram S, Banka HC, Vassallo G, et al. Anticipatory banking of samples enables diagnosis of adenylosuccinase deficiency following molecular autopsy in an infant with vacuolating leukoencephalopathy. Am J Med Genet A 2023;191(1):234-7. PMID 36271826
74: Spiegel EK, Colman RF, Patterson D. Adenylosuccinate lyase deficiency. Mol Genet Metab 2006;89(1-2):19-31. PMID 16839792
75: Stathis SL, Cowley DM, Broe D. Autism and adenylosuccinase deficiency. J Am Acad Child Adolesc Psychiatry 2000;39(3):274-25. PMID 10714045
76: Stone RL, Aimi J, Barshop BA, et al. A mutation in adenylosuccinate lyase associated with mental retardation and autistic features. Nat Genet 1992;1(1):59-63. PMID 1302001
77: Stone TW, Duley JA, Simmonds HA, Vincent MF, van den Berghe G. Succinylpurines do not modify glutamate or adenosine effects in the CNS. Adv Exp Med Biol 1998a;431:119-23. PMID 9598056
78: Stone TW, Roberts LA, Morris BJ. Succinylpurines induce neuronal damage in the rat brain. Adv Exp Med Biol 1998b;431:185-9. PMID 9598056
79: The Human Gene Mutation Database. Available at: http://www.hgmd.cf.ac.uk/ac/index.php. Accessed 2017.
80: Valik D, Miner PT, Jones JD. First U.S. case of adenylosuccinate lyase deficiency with severe hypotonia. Pediatr Neurol 1997;16(3):252-5. PMID 9165520
81: Van den Bergh F, Vincent MF, Jaeken J, Van den Berghe G. Radiochemical assay of adenylosuccinase: demonstration of parallel loss of activity toward both adenylosuccinate and succinylaminoimidazole carboxamide ribotide in liver of patients with the enzyme defect. Anal Biochem 1991;193(2):287-91. PMID 1872474
82: Van den Bergh F, Vincent MF, Jaeken J, Van den Berghe G. Residual adenylosuccinase activities in fibroblasts of adenylosuccinase-deficient children: parallel deficiency with adenylosuccinate and succinyl-AICAR in profoundly retarded patients and non-parallel deficiency in a mildly retarded girl. J Inherit Metab Dis 1993;16(2):415-24. PMID 8412002
83: Van den Bergh F, Bosschaart AN, Hageman G, Duran M, Poll The B. Adenylosuccinase deficiency with neonatal onset severe epileptic seizures and sudden death. Neuropediatrics 1998;29(1):51-3. PMID 9553952
84: Van den Berghe G, Bontemps F, Vincent MF, Van den Bergh F. The purine nucleotide cycle and its molecular defects. Prog Neurobiol 1992;39(5):547-61. PMID 1529104
85: Van den Berghe G, Jaeken J. Adenylosuccinase deficiency. Adv Exp Med Biol 1986;195 Pt A:27-33. PMID 3014834
86: van Werkhoven MA, Duley JA, McGown I, Munce T, Freeman JL, Pitt JJ. Early diagnosis of adenylosuccinate lyase deficiency using a high-throughput screening method and a trial of oral S-adenosyl-l-methionine as a treatment method. Dev Med Child Neurol 2013;55(11):1060-4. PMID 23937257
87: Vliet LK, Wilkinson TG 2nd, Duval N, et al. Molecular characterization of the Adel mutant of Chinese hamster ovary cells: a cellular model of adenylosuccinate lyase deficiency. Mol Genet Metab 2011;102(1):61-8. PMID 20884265
88: Wadman SK, de Bree PK, Duran M, de Jonge HF. Detection of inherited adenylosuccinase deficiency by two dimensional thin layer chromatography of urinary imidazoles. Adv Exp Med Biol 1986;195 Pt A:21-5. PMID 3728154
89: Wang XC, Wang T, Liu RH, et al. Child with adenylosuccinate lyase deficiency caused by a novel complex heterozygous mutation in the ADSL gene: a case report. World J Clin Cases 2022;10(30):11082-9. PMID 36338215
90: Ware TL, Mackay MT, Harvey AS, Freeman JL. Epileptic spasms: experience with a high-dose oral corticosteroid protocol. J Paediatr Child Health 2012;48(11):985-9. PMID 23039949
91: Zeman J, Krijt J, Stratilová L, et al. Abnormalities in succinylpurines in fumarase deficiency: possible role in pathogenesis of CNS impairment. J Inherit Metab Dis 2000;23(4):371-4. PMID 10896297
92: Zikanova M, Krijt J, Skopova V, Krijt M, Baresova V, Kmoch S. Screening for adenylosuccinate lyase deficiency using tandem mass spectrometry analysis of succinylpurines in neonatal dried blood spots. Clin Biochem 2015;48(1-2):2-7. PMID 25445730
93: Zikanova M, Skopova V, Hnizda A, Krijt J, Kmoch S. Biochemical and structural analysis of 14 mutant adsl enzyme complexes and correlation to phenotypic heterogeneity of adenylosuccinate lyase deficiency. Hum Mutat 2010;31(4):445-55. PMID 20127976
94: Zulfiqar M, Lin DD, Van der Graaf M, et al. Novel proton MR spectroscopy findings in adenylosuccinate lyase deficiency. J Magn Reson Imaging 2013;37(4):974-80. PMID 23055421

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Author

Douglas J Lanska MD MS MSPH

Dr. Lanska of the University of Wisconsin School of Medicine and Public Health and the Medical College of Wisconsin has no relevant financial relationships to disclose.
See Profile

Former Authors

Jaak Jaeken MD PhD
Georges Van den Berghe MD
Agnieszka Jurecka MD PhD
Sho T Yano MD
Carlos R Ferreira MD
Tyler Reimschisel MD

Patient Profile

Age range of presentation: 0 to 23 months
Sex preponderance: male=female
Heredity: heredity typical: autosomal recessive
Population groups selectively affected: none
Occupation groups selectively affected: none

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Adenylosuccinate lyase deficiency

Differential Diagnosis

pyridoxine responsive seizures
pyridox(am)ine-5'-phosphate oxidase deficiency
folinic acid-responsive seizures
3-phosphoglycerate dehydrogenase deficiency
hyperinsulinemic hypoglycemia
- convulsions
- unexplained psychomotor retardation
- hypotonia
- autistic features
- neurologic disease without clear etiology
- nonketotic hyperglycinemia
- D-2-hydroxyglutaric aciduria
- mitochondrial glutamate transporter defect
- peroxisomal biogenesis defects
- respiratory chain disorders
- sulfite oxidase deficiency
- Menkes disease
- Angelman syndrome
- Rett syndrome

Also Relevant

Autism spectrum disorder
Cerebellar hypoplasia, dysplasia, and enlargement
Epilepsy
Intellectual disability

Clinical Categories

Neurogenetic Disorders

Web References

Testing

Adenylosuccinase Deficiency

Adenylosuccinate lyase deficiency

Adenylosuccinate lyase deficiency

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Differential diagnosis

Confusing conditions

Diagnostic workup

Management

Special considerations

Anesthesia

Media

References

Contributors

Author

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview.
Start a Free Account
to access the full version.

Questions or Comment?

Also in This Category

Hypermethioninemia

Multiple acyl-CoA dehydrogenase deficiency

Medium-chain acyl-CoA dehydrogenase deficiency

Long-chain fatty acid oxidation defects

Nonketotic hyperglycinemia

Leukodystrophies

Mucopolysaccharidoses

Alexander disease

	• The prevalence of adenylosuccinate lyase deficiency is unknown.
	• More than 80 patients with adenylosuccinate lyase deficiency have been reported in populations across the world.

Adenylosuccinate lyase deficiency

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Differential diagnosis

Confusing conditions

Diagnostic workup

Management

Special considerations

Anesthesia

Media

References

Contributors

Author

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Hypermethioninemia

Multiple acyl-CoA dehydrogenase deficiency

Medium-chain acyl-CoA dehydrogenase deficiency

Long-chain fatty acid oxidation defects

Nonketotic hyperglycinemia

Leukodystrophies

Mucopolysaccharidoses

Alexander disease

This is an article preview.
Start a Free Account
to access the full version.